These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 9660700)
21. The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity. Tonello F; Montecucco C Mol Aspects Med; 2009 Dec; 30(6):431-8. PubMed ID: 19665472 [TBL] [Abstract][Full Text] [Related]
22. New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis. Beierlein JM; Anderson AC Curr Med Chem; 2011; 18(33):5083-94. PubMed ID: 22050756 [TBL] [Abstract][Full Text] [Related]
23. Small molecule inhibitors of anthrax edema factor. Jiao GS; Kim S; Moayeri M; Thai A; Cregar-Hernandez L; McKasson L; O'Malley S; Leppla SH; Johnson AT Bioorg Med Chem Lett; 2018 Jan; 28(2):134-139. PubMed ID: 29198864 [TBL] [Abstract][Full Text] [Related]
24. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Turk BE; Wong TY; Schwarzenbacher R; Jarrell ET; Leppla SH; Collier RJ; Liddington RC; Cantley LC Nat Struct Mol Biol; 2004 Jan; 11(1):60-6. PubMed ID: 14718924 [TBL] [Abstract][Full Text] [Related]
25. Screening inhibitors of anthrax lethal factor. Tonello F; Seveso M; Marin O; Mock M; Montecucco C Nature; 2002 Jul; 418(6896):386. PubMed ID: 12140548 [TBL] [Abstract][Full Text] [Related]
27. The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors. Menard A; Papini E; Mock M; Montecucco C Biochem J; 1996 Dec; 320 ( Pt 2)(Pt 2):687-91. PubMed ID: 8973585 [TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibody against the poly-gamma-D-glutamic acid capsule of Bacillus anthracis protects mice from enhanced lethal toxin activity due to capsule and anthrax spore challenge. Jang J; Cho M; Lee HR; Cha K; Chun JH; Hong KJ; Park J; Rhie GE Biochim Biophys Acta; 2013 Mar; 1830(3):2804-12. PubMed ID: 23201204 [TBL] [Abstract][Full Text] [Related]
30. Development of an improved vaccine for anthrax. Leppla SH; Robbins JB; Schneerson R; Shiloach J J Clin Invest; 2002 Jul; 110(2):141-4. PubMed ID: 12122102 [No Abstract] [Full Text] [Related]
31. Peptide inhibitors MAP the way towards fighting anthrax pathogenesis. DeCathelineau AM; Bokoch GM Biochem J; 2006 Apr; 395(1):e1-3. PubMed ID: 16541485 [TBL] [Abstract][Full Text] [Related]
32. Immune system paralysis by anthrax lethal toxin: the roles of innate and adaptive immunity. Fukao T Lancet Infect Dis; 2004 Mar; 4(3):166-70. PubMed ID: 14998502 [TBL] [Abstract][Full Text] [Related]
34. Bacillus anthracis: a multi-faceted role for anthrax lethal toxin in thwarting host immune defenses. Xu L; Frucht DM Int J Biochem Cell Biol; 2007; 39(1):20-4. PubMed ID: 17008119 [TBL] [Abstract][Full Text] [Related]
35. Discovery of the anthrax toxin: the beginning of studies of virulence determinants regulated in vivo. Smith H Int J Med Microbiol; 2002 Feb; 291(6-7):411-7. PubMed ID: 11890538 [TBL] [Abstract][Full Text] [Related]
37. Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax. Aziz MA; Singh S; Anand Kumar P; Bhatnagar R Biochem Biophys Res Commun; 2002 Dec; 299(3):345-51. PubMed ID: 12445805 [TBL] [Abstract][Full Text] [Related]
38. Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production. Fang H; Xu L; Chen TY; Cyr JM; Frucht DM J Immunol; 2006 May; 176(10):6155-61. PubMed ID: 16670324 [TBL] [Abstract][Full Text] [Related]
39. Editorial. Mock M; Montecucco C Mol Aspects Med; 2009 Dec; 30(6):345-6. PubMed ID: 19733583 [No Abstract] [Full Text] [Related]